NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center

About this trial

To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe.

To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men ≥18 years of age

Histologically documented prostatic adenocarcinoma with an NCCN risk group of high-risk or very high-risk. NCCN High Risk and Very High-Risk criteria shown below. (Network, N.C.C. (2021).

cT3a

Grade Group 4 or Grade Group 5

Disqualifiers

Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens, ketoconazole, or estrogens (5-α reductase inhibitors allowed), or LHRH agonists/antagonists

Currently enrolled in another interventional study

Concurrent treatment with systemic corticosteroids (prednisone dose >10 mg per day or equivalent) or other immunosuppressive drugs <14 days prior to treatment initiation Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted.

Known evidence of an active infection requiring systemic therapy such as uncontrolled human immunodeficiency virus (HIV), active hepatitis, or fungal infection. Uncomplicated urinary tract infection (UTI) does not qualify as an excluding infection.

Trial design

Design model

Single group

Treatments tested in this trial

  • Arm A: 177Lu rhPSMA-10.1

    Drug

    Participants will receive 177Lu rhPSMA-10.1 alone.

  • Arm B: 177Lu rhPSMA-10.1 plus Degarelix

    Drug

    Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix

Treatment groups

6 Participants
are divided into 1 treatment group
Group A: LeadIn: Treatment with 177Lu rhPSMA-10.1Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Time frame
through study completion; an average 1 year
2

Efficacy will be assess by measuring the radiation dose to the tumor (dosimetries) and PSA assessment

Time frame
Up to 6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

Blue Earth Therapeutics Ltd

Collaborator